文献速递乳腺癌

ECOG-ACRIN EA1131:基底亚型TNBC新辅助化疗后残留病灶的铂类对比卡培他滨随机III期试验

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
PubMed 文献 · J Clin Oncol · 2021-06-06

EA1131研究针对II-III期三阴性乳腺癌新辅助化疗后残留浸润性疾病≥1cm患者,随机接受铂类(卡铂或顺铂)每3周4周期或卡培他滨21天中14天每3周6周期。在308例(78%)基底亚型患者中,中位随访20个月、120例iDFS事件时,铂类3年iDFS为42%(95%CI 30-53),卡培他滨为49%(95%CI 39-59),铂类未显示非劣效或优效且3-4级毒性更常见,试验提前终止。

要点

  • 基底亚型TNBC新辅助化疗后残留病灶,铂类对比卡培他滨未改善iDFS且毒性更高。
  • 该人群3年iDFS低于预期(铂类42%、卡培他滨49%),亟需更好治疗。
  • 试验因无效提前终止,卡培他滨仍为该场景的辅助标准选择之一。

核心结论

  • 基底亚型三阴性乳腺癌新辅助化疗后残留病灶患者中,铂类对比卡培他滨未改善iDFS且3-4级毒性更常见。

研究设计与样本

  • 随机III期试验纳入临床II或III期TNBC新辅助化疗后乳腺残留浸润病灶≥1cm患者,随机接受铂类(卡铂或顺铂)每3周4周期或卡培他滨每3周14/21天6周期。
  • TNBC亚型(基底vs非基底)由残留病灶PAM50确定,采用非劣效设计并设优效替代假设,假定卡培他滨4年iDFS为67%。

主要发现

  • 基底亚型患者中,铂类3年iDFS为42%(95%CI 30-53),卡培他滨为49%(95%CI 39-59)。
  • 铂类3-4级毒性更常见。
  • 数据与安全监察委员会因进一步随访不太可能显示铂类非劣效或优效而建议终止试验。
  • 无论治疗如何,参与者3年iDFS均低于预期。

关键数值与推荐

  • 基底亚型TNBC残留病灶:铂类3年iDFS 42%(95%CI 30-53)vs 卡培他滨49%(95%CI 39-59)。

临床怎么用

  • 基底亚型TNBC新辅助化疗后残留病灶不推荐用铂类替代卡培他滨辅助治疗。
  • 卡培他滨仍是该高危人群的辅助治疗选择,但3年iDFS不理想,需探索更优方案。

局限性

  • 试验因无效提前终止,随访时间较短(中位20个月),iDFS事件仅占完全信息的61%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support the use of platinum agents in the TNBC basal subtype. The EA1131 trial hypothesized that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype TNBC treated with adjuvant platinum compared with capecitabine. PATIENTS AND METHODS: Patients with clinical stage II or III TNBC with ≥ 1 cm RD in the breast post-NAC were randomly assigned to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of 21 days every 3 weeks for six cycles. TNBC subtype (basal v nonbasal) was determined by PAM50 in the residual disease. A noninferiority design with superiority alternative was chosen, assuming a 4-year iDFS of 67% with capecitabine. RESULTS: Four hundred ten of planned 775 participants were randomly assigned to platinum or capecitabine between 2015 and 2021. After median follow-up of 20 months and 120 iDFS events (61% of full information) in the 308 (78%) patients with basal subtype TNBC, the 3-year iDFS for platinum was 42% (95% CI, 30 to 53) versus 49% (95% CI, 39 to 59) for capecitabine. Grade 3 and 4 toxicities were more common with platinum agents. The Data and Safety Monitoring Committee recommended stopping the trial as it was unlikely that further follow-up would show noninferiority or superiority of platinum. CONCLUSION: Platinum agents do not improve outcomes in patients with basal subtype TNBC RD post-NAC and are associated with more severe toxicity when compared with capecitabine. Participants had a lower than expected 3-year iDFS regardless of study treatment, highlighting the need for better therapies in this high-risk population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mayer IA, Zhao F, Arteaga CL, et al. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021. PMID: 34092112. doi:10.1200/JCO.21.00976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。